Benzothiazole aniline tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro

ACS Chem Neurosci. 2013 Nov 20;4(11):1501-12. doi: 10.1021/cn400146a. Epub 2013 Sep 9.

Abstract

Alzheimer's disease, Familial British dementia, Familial Danish dementia, Type 2 diabetes mellitus, plus Creutzfeldt-Jakob disease are associated with amyloid fibril deposition and oxidative stress. The antioxidant enzyme catalase is a neuroprotective amyloid binding protein. Herein the effects of catalase overexpression in SH-SY5Y neuronal cells on the toxicity of amyloid-β (Aβ), amyloid-Bri (ABri), amyloid-Dan (ADan), amylin (IAPP), and prion protein (PrP) peptides were determined. Results showed catalase overexpression was neuroprotective against Aβ, ABri, ADan, IAPP, and PrP peptides. The catalase inhibitor 3-amino-1,2,4-triazole (3-AT) and catalase-amyloid interaction inhibitor benzothiazole aniline tetra(ethylene glycol) (BTA-EG4) significantly enhanced neurotoxicity of amyloid peptides in catalase overexpressing neuronal cells. This suggests catalase neuroprotection involves breakdown of hydrogen peroxide (H2O2) plus a direct binding interaction between catalase and the Aβ, ABri, ADan, IAPP, and PrP peptides. Kisspeptin 45-50 had additive neuroprotective actions against the Aβ peptide in catalase overexpressing cells. The effects of 3-AT had an intracellular site of action, while catalase-amyloid interactions had an extracellular component. These results suggest that the 3-AT and BTA-EG4 compounds may be able to inhibit endogenous catalase mediated neuroprotection. Use of BTA-EG4, or compounds that inhibit catalase binding to amyloid peptides, as potential therapeutics for Neurodegenerative diseases may therefore result in unwanted effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / enzymology
  • Alzheimer Disease / genetics
  • Alzheimer Disease / pathology
  • Amitrole / chemistry
  • Amitrole / toxicity*
  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / metabolism
  • Aniline Compounds / chemistry
  • Aniline Compounds / toxicity*
  • Benzothiazoles / chemistry
  • Benzothiazoles / toxicity*
  • Catalase / antagonists & inhibitors
  • Catalase / biosynthesis
  • Catalase / genetics*
  • Cell Line, Tumor
  • Creutzfeldt-Jakob Syndrome / enzymology
  • Creutzfeldt-Jakob Syndrome / genetics
  • Creutzfeldt-Jakob Syndrome / pathology
  • Dementia / enzymology
  • Dementia / genetics
  • Dementia / pathology
  • Diabetes Mellitus, Type 2 / enzymology
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / pathology
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / toxicity*
  • Humans
  • Neurons / drug effects
  • Neurons / enzymology
  • Neurons / pathology
  • Neuroprotective Agents / antagonists & inhibitors*
  • Neuroprotective Agents / therapeutic use
  • Protein Binding / drug effects
  • Protein Binding / genetics
  • Up-Regulation / drug effects
  • Up-Regulation / genetics

Substances

  • 2-(4'-(dimethylamino)phenyl)benzothiazole
  • Amyloid beta-Peptides
  • Aniline Compounds
  • Benzothiazoles
  • Enzyme Inhibitors
  • Neuroprotective Agents
  • CAT protein, human
  • Catalase
  • Amitrole